The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals.

Rapamycin, also known as sirolimus, has demonstrated great potential for application in longevity medicine. However, the dynamics of low-dose rapamycin bioavailability, and any differences in bioavailability for different formulations (e.g.